Developer docs
API playgroundTry for free, no card

Search company profiles

Dynamic Biosensors

Full company profile

uuid0009ck7

Namestring
Dynamic Biosensors
Legal namestring
Bruker Dynamic Biosensors, Zweigniederlassung der Bruker Daltonics GmbH & Co. KG
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Dynamic Biosensors, operating as Bruker Biosensors since its October 2024 acquisition by Bruker Corporation, develops biophysical instruments for molecular interaction analysis built on two proprietary technology platforms: switchSENSE, which uses electrically controllable DNA nanolevers attached to gold microelectrodes, and single-cell Interaction Cytometry (scIC/RT-IC), which measures binding kinetics directly on living cells. The product portfolio spans the heliX and heliX+ biosensor instruments (with dual-color detection and multiplexing capabilities), the heliXcyto instrument for real-time interaction cytometry on cells, and the proFIRE system for protein-DNA conjugate preparation and purification, all unified under the heliOS software platform (switchCONTROL, switchBUILD, switchANALYSIS) and supported by proprietary consumable chips, adapter strands, and reagents. The technology is supported by more than 80 peer-reviewed publications covering applications from PROTAC ternary kinetics and bispecific antibody profiling to RNA in vitro evolution and SARS-CoV-2 binding characterization.

The company primarily serves pharmaceutical and biotechnology companies engaged in drug discovery (including novel therapeutic modalities such as PROTACs and bispecific antibodies), with academic and research institutions and government research bodies as secondary segments. Documented users include the Kolmar Group at TU Darmstadt, the Rothemund lab at Caltech, the Hoffmann/Kath-Schorr lab (RNA research), and the Fraunhofer Institute for Cellular Therapies and Immunology (IZI-BB).

The business model follows a classic tools-and-consumables structure: high-value capital equipment sales (heliX, heliX+, heliXcyto, proFIRE instruments) generate initial revenue, followed by recurring revenue from proprietary chips, conjugation kits, and reagents required for ongoing operation. Go-to-market combines enterprise field sales with a demo-led evaluation program (instruments brought to customer labs for hands-on testing), inside sales operations, a dedicated e-commerce shop for consumables, active conference exhibition presence, and a recurring scientific webinar series. International reach is achieved through direct offices in Munich (HQ), Billerica MA (US), and Glasgow (UK), supplemented by distribution partners across Poland, China, Japan, Singapore, and South Korea.

Short descriptiontext

Dynamic Biosensors (now Bruker Biosensors) develops biophysical instruments for molecular interaction analysis using proprietary switchSENSE DNA nanolever and scIC single-cell cytometry technologies, serving pharmaceutical, biotechnology, and academic researchers in drug discovery applications.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMunich, Germany
HQ citystring
Munich
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biophysical instruments, molecular interaction analysis, biosensor technology, drug discovery tools, kinetics characterization
Industry2 codes
PRIMARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Other Measuring and Controlling Device Manufacturing334519
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • Industrial Instruments For Measurement, Display, And Control3823
Product category
Biophysical Research Instruments
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Instrument Sales
TypeHardware Sales
Description

Sale of biophysical analysis instruments including heliX, heliX+, heliXcyto, DRX, and proFIRE systems. Instruments are high-value capital equipment sold to pharmaceutical/biotech companies and academic institutions.

dynamic-biosensors.com
2Consumables and Chips
TypeHardware Sales
Description

Recurring revenue from sale of heliX chips, heliXcyto chips, consumables, and reagents. Consumables are required for ongoing instrument operation and measurements.

dynamic-biosensors.com
3Conjugation Kits and Reagents
TypeHardware Sales
Description

Sale of proFIRE conjugation kits, labelling kits, and easy-to-use protocols for protein-DNA conjugate preparation.

dynamic-biosensors.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Bruker Biosensors
Description

Post-acquisition brand name for the Dynamic Biosensors business unit within Bruker, combining high-throughput SPR portfolio with switchSENSE and scIC technologies.

dynamic-biosensors.com
Core offering1 text field

Dynamic Biosensors develops and manufactures biophysical analysis instruments for molecular interaction studies used in drug discovery and life science research. Its proprietary switchSENSE® platform uses electrically controllable DNA nanolevers on gold microelectrodes to measure kinetics, affinity, and conformational changes, while its single-cell Interaction Cytometry (scIC) technology enables real-time binding measurements on living cells. The product portfolio includes the heliX/heliX+ and heliXcyto instruments, the proFIRE protein-DNA conjugation system, heliOS software, and consumable chips.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • RT-IC can detect low-expression molecules down to ~1000 molecules/cell
+2 more records
Product overview1 text field

Dynamic Biosensors offers a unified platform of biosensor instruments and technologies for molecular interaction analysis. The core portfolio consists of the switchSENSE® technology platform (using DNA nanolevers on gold microelectrodes) and scIC (single-cell Interaction Cytometry) for molecule-cell interactions. The heliX®/heliX+ instruments are the primary analytical platforms compatible with switchSENSE®, featuring multi-spot sensing with dual-color detection. The heliXcyto extends capabilities to real-time kinetic measurements on living cells. The proFIRE® system provides dedicated protein-DNA conjugation instruments. These products share the heliOS software ecosystem and are supported by a range of consumable chips. The company was acquired by Bruker Corporation in October 2024, forming the Bruker Biosensors business unit.

Product and service8 records
1switchSENSE®
CategoryCore Technology
Description

Biophysical research technology platform using DNA nanolevers attached to gold microelectrodes for analyzing molecular interactions, enabling measurement of kinetics, affinity, dose response, conformational changes, and enzymatic activity.

2heliX® / heliX+ Biosensor
CategoryInstrument
Description

Versatile biosensor instruments compatible with switchSENSE technology for comprehensive biophysical characterization. The heliX+ features dual-color detection with two sensor spots, two lasers, four single-photon detectors, and multiplexing capabilities.

3heliXcyto Biosensor
CategoryInstrument
Description

Real-Time Interaction Cytometry (RT-IC) instrument for measuring molecular binding kinetics directly on living cells using single-cell interaction cytometry technology. Features integrated CCD camera, temperature-controlled chip and sample trays, and automated workflow for cell immobilization.

4proFIRE®
CategoryInstrument
Description

Conjugation system for preparation, purification, and analysis of protein-DNA conjugates. Features a 2-step workflow combining protein-DNA conjugation with automated purification, including coupling reagents, high-performance purification, and automatic conjugate recognition.

5heliOS Software
CategorySoftware
Description

Software platform for controlling heliX instruments, including switchCONTROL, switchBUILD, and switchANALYSIS modules for experiment control, workflow design, and data analysis.

6heliX Adapter chip
CategoryConsumable
Description

Sensor chip compatible with heliX instruments for molecular interaction analysis.

7heliXcyto chip
CategoryConsumable
Description

Specialized chip for RT-IC measurements with cell traps suitable for cells from 6 to 25 µm diameter.

8scIC (single-cell Interaction Cytometry)
CategoryCore Technology
Description

Technology enabling real-time measurement of molecules binding to membrane targets on living cells, combining biophysics and cytometry principles to measure association/dissociation rates, affinity, avidity, and stability directly on cells.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Fraunhofer Institute for Cellular Therapies and Immunology (IZI-BB)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-07-27
Description

Collaborative research project 'CoronaSense' using switchSENSE technology to characterize binding interactions of SARS-CoV-2 spike proteins with receptors, supporting development of anti-viral drugs and diagnostic tests. Published in Nature Scientific Reports 2022.

dynamic-biosensors.com
Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Bruker is now the parent company of Dynamic Biosensors (Bruker Biosensors business) and also operates the SPR #64 platform. As parent and a broader biophysical instrumentation incumbent, Bruker provides both expansion runway and adjacent competition within its own portfolio.

TypeDirect peer
Description

Cytiva's Biacore is the dominant SPR platform for protein interaction kinetics analysis. It directly competes with switchSENSE-based heliX instruments for the same pharma/biotech drug discovery buying centers, though using optical SPR vs. electrical DNA-nanolever detection.

TypeDirect peer
Description

Nicoya develops benchtop SPR biosensor instruments (e.g., OpenSPR) for molecular interaction analysis targeting academic and biotech researchers, overlapping with switchSENSE's kinetics and affinity use cases.

TypeBroad incumbent
Description

Sartorius is a major bioprocessing and lab products supplier serving pharma and biotech R&D with a portfolio that includes cell analysis and analytical instrumentation adjacent to molecular interaction workflows.

TypeBroad incumbent
Description

Bio-Rad's life science research segment serves pharma and academic customers with protein interaction and biophysical characterization tools, providing some overlap with switchSENSE affinity and kinetics applications.

TypeBroad incumbent
Description

Thermo Fisher supplies broad analytical instrumentation (including SPR via subsidiary history) and life science reagents serving pharma biotech discovery, making it a broad incumbent with potential overlap on biophysical characterization budgets.

TypeDirect peer
Description

Carterra's high-throughput SPR (e.g., LSA) and kinetic analysis instruments target antibody and biologics characterization customers in pharma and CROs, directly competing with heliX/heliX+ for molecular interaction analysis workflows.

TypeDirect peer
Description

Gator Bio manufactures label-free biosensor instruments (e.g., GatorPrime) for real-time kinetics and antibody screening, competing with heliX instruments for pharma/biotech protein interaction characterization.

TypeEmerging player
Description

Reichert specializes in surface plasmon resonance and label-free analytical instruments for biomolecular interaction research, providing a niche SPR-focused overlap with switchSENSE technology in academic and pharma environments.

TypeBroad incumbent
Description

Agilent produces analytical and life science instrumentation including mass spectrometry and biophysical tools serving pharma biotech customers, making it a broad incumbent with overlapping surface plasmon resonance-adjacent capabilities.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance13 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Dynamic Biosensors

Biophysical Research Instrumentsdynamic-biosensors.com

Dynamic Biosensors (now Bruker Biosensors) develops biophysical instruments for molecular interaction analysis using proprietary switchSENSE DNA nanolever and scIC single-cell cytometry technologies, serving pharmaceutical, biotechnology, and academic researchers in drug discovery applications.

What Dynamic Biosensors does

Dynamic Biosensors, operating as Bruker Biosensors since its October 2024 acquisition by Bruker Corporation, develops biophysical instruments for molecular interaction analysis built on two proprietary technology platforms: switchSENSE, which uses electrically controllable DNA nanolevers attached to gold microelectrodes, and single-cell Interaction Cytometry (scIC/RT-IC), which measures binding kinetics directly on living cells. The product portfolio spans the heliX and heliX+ biosensor instruments (with dual-color detection and multiplexing capabilities), the heliXcyto instrument for real-time interaction cytometry on cells, and the proFIRE system for protein-DNA conjugate preparation and purification, all unified under the heliOS software platform (switchCONTROL, switchBUILD, switchANALYSIS) and supported by proprietary consumable chips, adapter strands, and reagents. The technology is supported by more than 80 peer-reviewed publications covering applications from PROTAC ternary kinetics and bispecific antibody profiling to RNA in vitro evolution and SARS-CoV-2 binding characterization.

The company primarily serves pharmaceutical and biotechnology companies engaged in drug discovery (including novel therapeutic modalities such as PROTACs and bispecific antibodies), with academic and research institutions and government research bodies as secondary segments. Documented users include the Kolmar Group at TU Darmstadt, the Rothemund lab at Caltech, the Hoffmann/Kath-Schorr lab (RNA research), and the Fraunhofer Institute for Cellular Therapies and Immunology (IZI-BB).

The business model follows a classic tools-and-consumables structure: high-value capital equipment sales (heliX, heliX+, heliXcyto, proFIRE instruments) generate initial revenue, followed by recurring revenue from proprietary chips, conjugation kits, and reagents required for ongoing operation. Go-to-market combines enterprise field sales with a demo-led evaluation program (instruments brought to customer labs for hands-on testing), inside sales operations, a dedicated e-commerce shop for consumables, active conference exhibition presence, and a recurring scientific webinar series. International reach is achieved through direct offices in Munich (HQ), Billerica MA (US), and Glasgow (UK), supplemented by distribution partners across Poland, China, Japan, Singapore, and South Korea.

Dynamic Biosensors firmographics

Firmographics
Name
Dynamic Biosensors
Legal name
Bruker Dynamic Biosensors, Zweigniederlassung der Bruker Daltonics GmbH & Co. KG
Website
https://dynamic-biosensors.com
Company type
Private
Founded year
2013
Operating status
Acquired
Headcount range
51–100 employees
Short description
Dynamic Biosensors (now Bruker Biosensors) develops biophysical instruments for molecular interaction analysis using proprietary switchSENSE DNA nanolever and scIC single-cell cytometry technologies, serving pharmaceutical, biotechnology, and academic researchers in drug discovery applications.
Ownership category
akta.pro rank

Dynamic Biosensors industry classification

Industry
Product category
Biophysical Research Instruments
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Other Measuring and Controlling Device Manufacturing (334519)
SIC
Laboratory Analytical Instruments (3826), Industrial Instruments For Measurement, Display, And Control (3823)
akta.pro industry
PRIMARYHDAHALAK
Biosensors & Lab-on-Chip (BioMEMS)
SECONDARYHLAGAIAE
Microscopy, Imaging & Flow Cytometry Instruments

Keywords

  • Biophysical instruments
  • Molecular interaction analysis
  • Biosensor technology
  • Drug discovery tools
  • Kinetics characterization

Where Dynamic Biosensors is headquartered

Location

Headquarters

HQ city
Munich
HQ country
Germany
HQ region
Europe

Offices8 records

Markets served

Dynamic Biosensors business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Instrument Sales: Sale of biophysical analysis instruments including heliX, heliX+, heliXcyto, DRX, and proFIRE systems. Instruments are high-value capital equipment sold to pharmaceutical/biotech companies and academic institutions.
  2. Consumables and Chips: Recurring revenue from sale of heliX chips, heliXcyto chips, consumables, and reagents. Consumables are required for ongoing instrument operation and measurements.
  3. Conjugation Kits and Reagents: Sale of proFIRE conjugation kits, labelling kits, and easy-to-use protocols for protein-DNA conjugate preparation.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Dynamic Biosensors product offering

Product offering

Core offering

Dynamic Biosensors develops and manufactures biophysical analysis instruments for molecular interaction studies used in drug discovery and life science research. Its proprietary switchSENSE® platform uses electrically controllable DNA nanolevers on gold microelectrodes to measure kinetics, affinity, and conformational changes, while its single-cell Interaction Cytometry (scIC) technology enables real-time binding measurements on living cells. The product portfolio includes the heliX/heliX+ and heliXcyto instruments, the proFIRE protein-DNA conjugation system, heliOS software, and consumable chips.

Product overview

Dynamic Biosensors offers a unified platform of biosensor instruments and technologies for molecular interaction analysis. The core portfolio consists of the switchSENSE® technology platform (using DNA nanolevers on gold microelectrodes) and scIC (single-cell Interaction Cytometry) for molecule-cell interactions. The heliX®/heliX+ instruments are the primary analytical platforms compatible with switchSENSE®, featuring multi-spot sensing with dual-color detection. The heliXcyto extends capabilities to real-time kinetic measurements on living cells. The proFIRE® system provides dedicated protein-DNA conjugation instruments. These products share the heliOS software ecosystem and are supported by a range of consumable chips. The company was acquired by Bruker Corporation in October 2024, forming the Bruker Biosensors business unit.

Differentiator

Problem solved

Functional benefit

Brands

  • Bruker Biosensors: Post-acquisition brand name for the Dynamic Biosensors business unit within Bruker, combining high-throughput SPR portfolio with switchSENSE and scIC technologies.

Products and services

  • switchSENSE® Biophysical research technology platform using DNA nanolevers attached to gold microelectrodes for analyzing molecular interactions, enabling measurement of kinetics, affinity, dose response, conformational changes, and enzymatic activity.
  • heliX® / heliX+ Biosensor Versatile biosensor instruments compatible with switchSENSE technology for comprehensive biophysical characterization. The heliX+ features dual-color detection with two sensor spots, two lasers, four single-photon detectors, and multiplexing capabilities.
  • heliXcyto Biosensor Real-Time Interaction Cytometry (RT-IC) instrument for measuring molecular binding kinetics directly on living cells using single-cell interaction cytometry technology. Features integrated CCD camera, temperature-controlled chip and sample trays, and automated workflow for cell immobilization.
  • proFIRE® Conjugation system for preparation, purification, and analysis of protein-DNA conjugates. Features a 2-step workflow combining protein-DNA conjugation with automated purification, including coupling reagents, high-performance purification, and automatic conjugate recognition.
  • heliOS Software Software platform for controlling heliX instruments, including switchCONTROL, switchBUILD, and switchANALYSIS modules for experiment control, workflow design, and data analysis.
  • heliX Adapter chip Sensor chip compatible with heliX instruments for molecular interaction analysis.
  • heliXcyto chip Specialized chip for RT-IC measurements with cell traps suitable for cells from 6 to 25 µm diameter.
  • scIC (single-cell Interaction Cytometry) Technology enabling real-time measurement of molecules binding to membrane targets on living cells, combining biophysics and cytometry principles to measure association/dissociation rates, affinity, avidity, and stability directly on cells.

Quantifiable outcome

  • RT-IC can detect low-expression molecules down to ~1000 molecules/cell
  • +2 more outcomes

Companies that use Dynamic Biosensors

Customer profile

Named customers6 records

Segments2 records

Ideal customer profiles3 records

Dynamic Biosensors technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Dynamic Biosensors partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Fraunhofer Institute for Cellular Therapies and Immunology (IZI-BB)minorStrategic or Co-development Partner · 27 July 2022Collaborative research project 'CoronaSense' using switchSENSE technology to characterize binding interactions of SARS-CoV-2 spike proteins with receptors, supporting development of anti-viral drugs and diagnostic tests. Published in Nature Scientific Reports 2022.

Scale indicators4 records

Expansion highlights5 records

Dynamic Biosensors competitors and assessment

Company assessment

Broad incumbents

  • Bruker Corporation: Bruker is now the parent company of Dynamic Biosensors (Bruker Biosensors business) and also operates the SPR #64 platform. As parent and a broader biophysical instrumentation incumbent, Bruker provides both expansion runway and adjacent competition within its own portfolio.
  • Sartorius AG: Sartorius is a major bioprocessing and lab products supplier serving pharma and biotech R&D with a portfolio that includes cell analysis and analytical instrumentation adjacent to molecular interaction workflows.
  • Bio-Rad Laboratories: Bio-Rad's life science research segment serves pharma and academic customers with protein interaction and biophysical characterization tools, providing some overlap with switchSENSE affinity and kinetics applications.
  • Thermo Fisher Scientific: Thermo Fisher supplies broad analytical instrumentation (including SPR via subsidiary history) and life science reagents serving pharma biotech discovery, making it a broad incumbent with potential overlap on biophysical characterization budgets.
  • Agilent Technologies: Agilent produces analytical and life science instrumentation including mass spectrometry and biophysical tools serving pharma biotech customers, making it a broad incumbent with overlapping surface plasmon resonance-adjacent capabilities.

Direct peers

  • Cytiva (Biacore): Cytiva's Biacore is the dominant SPR platform for protein interaction kinetics analysis. It directly competes with switchSENSE-based heliX instruments for the same pharma/biotech drug discovery buying centers, though using optical SPR vs. electrical DNA-nanolever detection.
  • Nicoya Lifesciences: Nicoya develops benchtop SPR biosensor instruments (e.g., OpenSPR) for molecular interaction analysis targeting academic and biotech researchers, overlapping with switchSENSE's kinetics and affinity use cases.
  • Carterra: Carterra's high-throughput SPR (e.g., LSA) and kinetic analysis instruments target antibody and biologics characterization customers in pharma and CROs, directly competing with heliX/heliX+ for molecular interaction analysis workflows.
  • Gator Bio: Gator Bio manufactures label-free biosensor instruments (e.g., GatorPrime) for real-time kinetics and antibody screening, competing with heliX instruments for pharma/biotech protein interaction characterization.

Emerging players

  • Reichert Technologies: Reichert specializes in surface plasmon resonance and label-free analytical instruments for biomolecular interaction research, providing a niche SPR-focused overlap with switchSENSE technology in academic and pharma environments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Dynamic Biosensors social profiles

Digital presence

Dynamic Biosensors compliance and trust

Trust signal

Compliance13 records

Dynamic Biosensors financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Dynamic Biosensors leadership team

Management profile

Number of profiles

Profiles7 records

Dynamic Biosensors funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Dynamic Biosensors M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dynamic Biosensors

What does Dynamic Biosensors do?

Dynamic Biosensors develops and manufactures biophysical analysis instruments for molecular interaction studies used in drug discovery and life science research. Its proprietary switchSENSE® platform uses electrically controllable DNA nanolevers on gold microelectrodes to measure kinetics, affinity, and conformational changes, while its single-cell Interaction Cytometry (scIC) technology enables real-time binding measurements on living cells. The product portfolio includes the heliX/heliX+ and heliXcyto instruments, the proFIRE protein-DNA conjugation system, heliOS software, and consumable chips.

Is Dynamic Biosensors a public or private company?

Dynamic Biosensors is a private company. It is classified as corporate owned and is currently acquired.

When was Dynamic Biosensors founded?

Dynamic Biosensors was founded in 2013. It employs 51 to 100 people.

Where is Dynamic Biosensors based?

Dynamic Biosensors is headquartered in Munich, Germany, in the Europe region.

How does Dynamic Biosensors make money?

Three revenue lines are on record. Instrument Sales are the primary driver. The others are consumables and Chips and conjugation Kits and Reagents.

Who are Dynamic Biosensors's main competitors?

Broad incumbents on record are Bruker Corporation, Sartorius AG, Bio-Rad Laboratories, Thermo Fisher Scientific and Agilent Technologies. Direct peers are Cytiva (Biacore), Nicoya Lifesciences, Carterra and Gator Bio. Reichert Technologies is listed as an emerging player.

Does Dynamic Biosensors have an API?

No public API is recorded for Dynamic Biosensors.

What industry is Dynamic Biosensors in?

Dynamic Biosensors's product category is Biophysical Research Instruments. Its primary akta.pro industry code is HDAHALAK, Biosensors & Lab-on-Chip (BioMEMS), with a secondary code of HLAGAIAE, Microscopy, Imaging & Flow Cytometry Instruments. Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comMarket Trend Analysis: The Impact of Recent Innovations on the Surface Plasmon Resonance MarketThe surface plasmon resonance market is projected to reach $2.3 billion by 2030, growing at a compound annual growth rate of 11.5%, driven by increased applications in biologics, personalized medicine, and drug discovery. In October 2024, Bruker Corporation completed the acquisition of Dynamic Biosensors GmbH, a Germany-based biosensor technology company, to strengthen its portfolio in biophysical instruments. Additionally, U.S.-based Carterra introduced its LSA XT high-throughput SPR platform in February 2023, offering improved sensitivity and sample throughput for pharmaceutical and biotech companies.Research NesterSynthetic Biosensors Market Size & Share, Growth Forecasts 2035The global synthetic biosensors market was valued at USD 29.88 billion in 2025 and is projected to exceed USD 61.58 billion by 2035, growing at a CAGR of 7.5% during the forecast period. Key recent developments include Bruker Corporation's acquisition of Dynamic Biosensors GmbH to expand its biophysical portfolio, and Biolinq's USD 58 million investment in a wearable patch-based biosensor for clinical trials and FDA approval. North America is anticipated to hold 46.9% market share by 2035, while Asia Pacific is projected to be the fastest-growing region driven by increasing adoption of nanotechnology-based biosensors and rising healthcare investments in countries like India and China.Mordor IntelligenceBiosensors Market Size, Trends & Growth Drivers 2030Mordor Intelligence projects the global biosensors market to grow from USD 28.5 billion in 2025 to USD 42.2 billion by 2030, driven by demand for continuous glucose monitoring and real-time diagnostics. Key developments include Dexcom receiving FDA clearance for its G7 CGM and Bruker acquiring Dynamic Biosensors to expand its surface-plasmon resonance capabilities.Stock TitanBruker Acquires Dynamic Biosensors, a Pioneer of Single-Cell Interaction Cytometry Systems for Drug DiscoveryBruker Corporation announced the acquisition of Dynamic Biosensors GmbH, a Munich-based developer of single-cell interaction cytometry systems for drug discovery. This transaction combines Dynamic Biosensors' heliX biosensor series with Bruker’s high-performance Surface Plasmon Resonance (SPR) portfolio to create a leading biosensors business. While financial details were not disclosed, Bruker expects additional revenues greater than $5 million from the acquisition in FY2025.